A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry

Recruiting now

Conditions studied: Neonatal Screening, Lysosomal Storage Diseases

In brief

The study will include all newborns in Normandie region for 3 years (about 105,000 births) for whom signed consent by one (or two) parents will be collected. Based on our previous pilot study (2011) assessing MCAD and PKU using tandem mass spectrometry-based method in Normandie region in which informed consents have been signed for all newborns (43,000) but we are expecting a great willingness to participate to this project. Thus, we are aiming to include 100,000 newborns, and the study will be continued until we reach at least this target. The primary objective is to evaluate the epidemiology of MPS1 and Pompe disease using dried blood samples in the first cohort of neonates tested in France (Normandie region).

Key facts

Study ID

NCT04393701

Run by

University Hospital, Rouen

People needed

100000

Starts

2021-03-08

Expected to finish

2026-12-08

Last updated by the study team

2026-05-27

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newborn in a Normandy maternity hospital
• Newborn participating in the National Neonatal Screening Program
• Holder(s) of parental authority having read and understood the information letter and signed the informed consent form

You may not qualify if…

• There are no criteria for non-inclusion in this study. Participation in the study, such as participation in the National Neonatal Screening Program, is not mandatory.

Where it is running

• Caen University Hospital — Caen, France (enrolling)
• Rouen University Hospital — Rouen, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.